Do statins beneficially or adversely affect glucose homeostasis?

@article{Kostapanos2010DoSB,
  title={Do statins beneficially or adversely affect glucose homeostasis?},
  author={M. Kostapanos and George Liamis and Haralampos J. Milionis and Moses S. Elisaf},
  journal={Current vascular pharmacology},
  year={2010},
  volume={8 5},
  pages={
          612-31
        }
}
The effect of statin treatment on glucose metabolism and the risk of diabetes remains an issue of controversy. Since statins are drugs commonly prescribed for the prevention of cardiovascular disease even in patients with prediabetes or diabetes, it is of great importance to identify the role of statin treatment on glucose homeostasis. In this review, we have scrutinized available data with regard to the effect of every drug of the class on glycemic outcomes. Experimental data describing… 
Risk and Benefits of Statins in Glucose Control Management of Type II Diabetes
TLDR
Evaluated statins in glucose control management of type 2 diabetes patients found that most of the statins give unfavorable side effects, and a dose‐dependent and time‐dependent effect was also observed in some statins which may be present among other statins as well.
Statins and their increased risk of inducing diabetes
TLDR
This review provides an update based on recent outstanding evidence on the statin effect on the risk of diabetes, and describes mechanisms potentially explaining adverse effects of statins on glucose homeostasis.
Statin Treatment-Induced Development of Type 2 Diabetes: From Clinical Evidence to Mechanistic Insights
TLDR
Clinically, these findings should encourage clinicians to consider diabetes monitoring in patients receiving statin therapy in order to ensure early diagnosis and appropriate management.
Variable effects of statins on glucose homeostasis parameters and their diabetogenic role
TLDR
The time-dependent diabetogenic effects of lipophilic and hydrophilic statins are prospectively compared to prevent hyperglycaemia in the short-term.
Pharmacological management of diabetic dyslipidemia
TLDR
Although the cholesterol ester transfer protein (CETP) inhibitors have shown harmful effects or lack of efficacy in completed clinical trials, the newer CETP inhibitors have promising effects on lipid profile and carbohydrate metabolism, but their effects on CVD risk and safety profile have not been assessed.
Effect of hypolipidemic treatment on glycemic profile in patients with mixed dyslipidemia.
TLDR
Both addition of ER-NA/LRPT and switch to the highest dose of rosuvastatin deteriorated glycemic profile in patients with mixed dyslipidemia, while add-on fenofibrate seems to increase insulin sensitivity.
Benefit–Risk Assessment of Rosuvastatin in the Treatment of Atherosclerosis and Related Diseases
TLDR
It was estimated that rosuvastatin-associated absolute hazards of muscle-, liver- and renal-related adverse effects are lower than the corresponding vascular benefits in moderate vascular risk individuals, but these data are subject to biases and need confirmation on a prospective basis.
Pitavastatin and carbohydrate metabolism: what is the evidence?
TLDR
Clinical and experimental evidence shows that pitavastatin increases adiponectin levels and reduces oxidative stress, effects that seem to be implicated in the beneficial effect of the drug on carbohydrate metabolism variables.
Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?
TLDR
The present review presents the available data regarding the effects of statin/fibrate combination in patients with T2DM and atherogenic mixed dyslipidemia.
Effect of Statins on Insulin Requirements during Non-Cardiac Surgery
TLDR
While the total amount of intraoperative insulin used was not statistically different between the statin users and non-users, a potentially important trend toward insulin resistance intraoperatively amongstatin users during major non-cardiac surgery is observed.
...
...